Back
Supernus Pharmaceuticals 10K Form
Sell
29
SUPN
Supernus Pharmaceuticals
Last Price:
35.54
Seasonality Move:
3.88%
7 Day Trial
ALL ACCESS PASS
$
7
Key Filings
| 2024-05-08 | 10Q | SUPN/Supernus Pharmaceuticals Quarterly |
| 2023-11-08 | 10Q | SUPN/Supernus Pharmaceuticals Quarterly |
| 2023-08-08 | 10Q | SUPN/Supernus Pharmaceuticals Quarterly |
| 2023-05-09 | 10Q | SUPN/Supernus Pharmaceuticals Quarterly |
| 2022-11-09 | 10Q | SUPN/Supernus Pharmaceuticals Quarterly |
| 2022-08-08 | 10Q | SUPN/Supernus Pharmaceuticals Quarterly |
Receive SUPN News And Ratings
See the #1 stock for the next 7 days that we like better than SUPN
SUPN Financial Statistics
Sales & Book Value
| Annual Sales: | $607.52M |
|---|---|
| Cash Flow: | $53.32M |
| Price / Cash Flow: | 11.41 |
| Annual Sales: | $18.24 |
| Price / Book: | 1.93 |
Profitability
| EPS (TTM): | 1.06960 |
|---|---|
| Net Income (TTM): | $59.71M |
| Gross Margin: | $523.74M |
| Return on Equity: | 6.32% |
| Return on Assets: | 4.58% |
Supernus Pharmaceuticals Earnings Forecast
Key Supernus Pharmaceuticals Financial Ratios
- The Gross Profit Margin over the past 15 years for SUPN is 86.21%.
- The Selling, General & Administrative Expenses for SUPN have been equal to 55.37% of Gross Profit Margin.
- The Research & Development expenses have been 15.08% of Revenue.
- The Interest Expense is 183.51% of Operating Income.
- The Net Earning history of SUPN is 0.22% of Total Revenues.
- Per Share Earnings over the last 17 years have been positive in 9 years.
Supernus Pharmaceuticals Stock Price Chart
Industry, Sector and Symbol
| Stock Exchange: | NASDAQ |
|---|---|
| Industry: | Pharmaceuticals |
| Sector: | Health Care |
| Current Symbol: | SUPN |
| CUSIP: | 868459 |
| Website: | supernus.com |
Debt
| Debt-to-Equity Ratio: | 0 |
|---|---|
| Current Ratio: | 2.2 |
| Quick Ratio: | 1.88 |
Price-to-Earnings
| Trailing P/E Ratio: | 1762.5 |
|---|---|
| Forward P/E Ratio: | 18.62 |
SUPN Technical Analysis vs Fundamental Analysis
Sell
29
Supernus Pharmaceuticals (SUPN)
is a Sell
Is Supernus Pharmaceuticals a Buy or a Sell?
-
Supernus Pharmaceuticals stock is rated a Sell
The current Supernus Pharmaceuticals [SUPN] share price is $35.25. The Score for SUPN is 29, which is 42% below its historic median score of 50, and infers higher risk than normal.